RKLB Stock Forecast & Price Target

Rocket Lab is favored because its launch heritage is already de-risking the story, with 97 successful launches, 21 in FY25, and 18 YTD at 100% mission success, while Electron demand remains strong and customer diversification spans commercial and government work. Its backlog of about $2.36B, expected 46% conversion within 12 months, and $2.4B of cash, equivalents, marketable securities, and restricted cash in 2Q26 suggest both revenue visibility and balance-sheet flexibility. Long term, Neutron’s ~13,000 kg capacity, $50M-$55M launch ASP, and reusability-driven margin upside, combined with the pending Iridium acquisition and more than $1B in SDA contract value, support an expanding end-to-end space platform.

Rocket Lab is facing a weaker fundamental setup because the Neutron delay to 2027 pushes back the company’s most important near-term growth catalyst and likely shifts the first revenue-generating launch into F4Q27, reducing FY27 launch monetization and pressuring FY27 revenue to $1,186.3M from $1,299.3M. The delay also worsens earnings visibility, with FY27 non-GAAP EPS cut to $0.07 from $0.13 and FY28 to $0.24 from $0.30, while management must still clear hydrostatic and cryo testing, integration, pad work, and launch licensing after the manufacturing defect fix. Beyond the timing slip, the stock faces execution, cost, and demand risks in a capital-intensive business with significant reliance on government contracts and a harsh technical environment.